| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT07472153 | PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point… | Metastatic Cervical Cancer | Recruiting |
| Phase 2 | |||
| NCT07380984 | PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL | Natural Killer/T-cell Lymphoma | Recruiting |
| NCT07403136 | Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC | Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT07381309 | Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for… | CRC | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06802835 | EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal… | Nasopharyngeal Cancinoma (NPC) | Recruiting |
| Phase 1 | |||
| NCT07318636 | NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as… | Resectable Non-small Cell Lung Cancer | Not Yet Recruiting |
| Not specified | |||
| NCT06417892 | Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line… | Gastric Cancer | Recruiting |